The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Status:
Unknown status
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Milatuzumab is effective in patients with
refractory chronic lymphocytic leukemia, and also to find out in which range of doses is a
response seen.